NASDAQ:INO - Inovio Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $3.69 -0.01 (-0.27 %) (As of 02/19/2019 04:00 PM ET)Previous Close$3.70Today's Range$3.63 - $3.7552-Week Range$3.64 - $6.30Volume3.24 million shsAverage Volume1.10 million shsMarket Capitalization$351.83 millionP/E Ratio-3.39Dividend YieldN/ABeta1.96 ProfileDiscussionAnalyst RatingsChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. The company is involved in conducting and planning clinical programs of its proprietary SynCon immunotherapies for HPV-caused pre-cancers and cancers; prostate, breast, lung, and pancreatic cancers; hepatitis C virus; hepatitis B virus; human immunodeficiency virus; Ebola virus; middle east respiratory syndrome; and Zika virus. Its partners and collaborators include MedImmune, LLC, The Wistar Institute, University of Pennsylvania, GeneOne Life Science Inc., Regeneron Pharmaceuticals, Inc., Genentech, Inc., Plumbline Life Sciences, Inc., the Parker Institute for Cancer Immunotherapy, Drexel University, National Microbiology Laboratory of the Public Health Agency of Canada, National Institute of Allergy and Infectious Diseases, United States Military HIV Research Program, U.S. Army Medical Research Institute of Infectious Diseases, National Institutes of Health, HIV Vaccines Trial Network, Defense Advanced Research Projects Agency, and Coalition for Epidemic Preparedness Innovations. Inovio Pharmaceuticals, Inc. was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania. Receive INO News and Ratings via Email Sign-up to receive the latest news and ratings for INO and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:INO Previous Symbol CUSIPN/A Webwww.inovio.com Phone267-440-4200Debt Debt-to-Equity RatioN/A Current Ratio3.34 Quick Ratio3.34Price-To-Earnings Trailing P/E Ratio-3.39 Forward P/E Ratio-3.69 P/E GrowthN/A Sales & Book Value Annual Sales$42.22 million Price / Sales8.33 Cash FlowN/A Price / Cash FlowN/A Book Value$1.58 per share Price / Book2.34Profitability EPS (Most Recent Fiscal Year)($1.09) Net Income$-88,200,000.00 Net Margins-232.58% Return on Equity-72.66% Return on Assets-52.58%Miscellaneous Employees280 Outstanding Shares95,347,000Market Cap$351.83 million OptionableOptionable Inovio Pharmaceuticals (NASDAQ:INO) Frequently Asked Questions What is Inovio Pharmaceuticals' stock symbol? Inovio Pharmaceuticals trades on the NASDAQ under the ticker symbol "INO." When did Inovio Pharmaceuticals' stock split? How did Inovio Pharmaceuticals' stock split work? Shares of Inovio Pharmaceuticals reverse split on the morning of Friday, June 6th 2014. The 1-4 reverse split was announced on Friday, May 23rd 2014. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 5th 2014. An investor that had 100 shares of Inovio Pharmaceuticals stock prior to the reverse split would have 25 shares after the split. How were Inovio Pharmaceuticals' earnings last quarter? Inovio Pharmaceuticals Inc (NASDAQ:INO) released its earnings results on Wednesday, May, 9th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.14) by $0.22. The biopharmaceutical company had revenue of $1.53 million for the quarter, compared to analysts' expectations of $7.50 million. Inovio Pharmaceuticals had a negative net margin of 232.58% and a negative return on equity of 72.66%. During the same period in the previous year, the firm posted ($0.31) EPS. View Inovio Pharmaceuticals' Earnings History. When is Inovio Pharmaceuticals' next earnings date? Inovio Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March 13th 2019. View Earnings Estimates for Inovio Pharmaceuticals. What price target have analysts set for INO? 4 Wall Street analysts have issued 1-year target prices for Inovio Pharmaceuticals' stock. Their predictions range from $8.00 to $14.00. On average, they expect Inovio Pharmaceuticals' share price to reach $10.75 in the next year. This suggests a possible upside of 189.0% from the stock's current price. View Analyst Price Targets for Inovio Pharmaceuticals. What is the consensus analysts' recommendation for Inovio Pharmaceuticals? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inovio Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Inovio Pharmaceuticals. What are Wall Street analysts saying about Inovio Pharmaceuticals stock? Here are some recent quotes from research analysts about Inovio Pharmaceuticals stock: 1. According to Zacks Investment Research, "Inovio’s progress with its lead pipeline candidate, VGX-3100, for the treatment of cervical dysplasia is encouraging. Apart from VGX-3100, Inovio also has some promising vaccine candidates in its portfolio, which are progressing well. Additionally, Inovio has collaboration with big pharma companies like Regeneron and AstraZeneca, which helps the company with the their derived expertise for further growth. Moreover, the company’s targeted cervical cancer market holds untapped potential. However, the company has no approved product in its portfolio andits excessive dependence on its partners for funding the development of its pipeline candidates raises a concern. Shares of the company have outperformed the industry in 2018. Loss estimates look stable ahead of the Q4 earnings release. Inovio has a positive record of earnings surprises in recent quarters." (2/14/2019) 2. HC Wainwright analysts commented, "Our 12-month price target is derived from a market value of the firm at $1.4B, which includes a discounted cash flow based asset value for 15% discount rate, 2% terminal growth rate and 80% probability of success. Risks include, but are not limited to: (1) failure of VGX-3100 in clinical trials; (2) failure of VGX-3100 to secure regulatory approval; (3) failure of VGX-3100 to achieve commercial success due to market size, penetration rate, and/or competition; and (4) potential dilution risk." (1/25/2019) 3. Maxim Group analysts commented, "Inovio announced the publication of a preclinical study highlighting the successful development of optimized DNA-encoded monoclonal antibodies (dMABs) targeting the immune checkpoint PD-1." (1/15/2019) Has Inovio Pharmaceuticals been receiving favorable news coverage? Media coverage about INO stock has trended somewhat positive this week, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Inovio Pharmaceuticals earned a media sentiment score of 0.9 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days. Who are some of Inovio Pharmaceuticals' key competitors? Some companies that are related to Inovio Pharmaceuticals include Tactile Systems Technology (TCMD), AtriCure (ATRC), Orthofix Medical (OFIX), K2M Group (KTWO), Luminex (LMNX), Cardiovascular Systems (CSII), Intersect ENT (XENT), Cryolife (CRY), Cerus (CERS), AngioDynamics (ANGO), SurModics (SRDX), OraSure Technologies (OSUR), Anika Therapeutics (ANIK), Antares Pharma (ATRS) and LeMaitre Vascular (LMAT). Who are Inovio Pharmaceuticals' key executives? Inovio Pharmaceuticals' management team includes the folowing people: Dr. J. Joseph Kim, CEO, Pres & Director (Age 50)Mr. Peter D. Kies, Chief Financial Officer (Age 56)Dr. Niranjan Y. Sardesai, Chief Operating Officer (Age 51)Dr. Mark L. Bagarazzi, Chief Medical Officer (Age 58)Dr. Laurent M. Humeau, Sr. VP of R&D and Chief Scientific Officer Who are Inovio Pharmaceuticals' major shareholders? Inovio Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.61%), D. E. Shaw & Co. Inc. (1.13%), Northern Trust Corp (1.10%), Geode Capital Management LLC (1.05%), Dimensional Fund Advisors LP (0.77%) and Defender Capital LLC. (0.61%). Company insiders that own Inovio Pharmaceuticals stock include David B Weiner, Jong Joseph Kim, Morton Collins, Peter Kies and Simon X Benito. View Institutional Ownership Trends for Inovio Pharmaceuticals. Which institutional investors are selling Inovio Pharmaceuticals stock? INO stock was sold by a variety of institutional investors in the last quarter, including Virtus ETF Advisers LLC, Millennium Management LLC, MetLife Investment Advisors LLC, New York State Common Retirement Fund, Emerald Advisers LLC, Bank of America Corp DE, Barclays PLC and Principal Financial Group Inc.. Company insiders that have sold Inovio Pharmaceuticals company stock in the last year include David B Weiner, Jong Joseph Kim, Peter Kies and Simon X Benito. View Insider Buying and Selling for Inovio Pharmaceuticals. Which institutional investors are buying Inovio Pharmaceuticals stock? INO stock was bought by a variety of institutional investors in the last quarter, including D. E. Shaw & Co. Inc., Defender Capital LLC., BlackRock Inc., Dimensional Fund Advisors LP, Geode Capital Management LLC, CIBC Private Wealth Group LLC, Rhumbline Advisers and Virtu Financial LLC. View Insider Buying and Selling for Inovio Pharmaceuticals. How do I buy shares of Inovio Pharmaceuticals? Shares of INO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Inovio Pharmaceuticals' stock price today? One share of INO stock can currently be purchased for approximately $3.72. How big of a company is Inovio Pharmaceuticals? Inovio Pharmaceuticals has a market capitalization of $354.69 million and generates $42.22 million in revenue each year. The biopharmaceutical company earns $-88,200,000.00 in net income (profit) each year or ($1.09) on an earnings per share basis. Inovio Pharmaceuticals employs 280 workers across the globe. What is Inovio Pharmaceuticals' official website? The official website for Inovio Pharmaceuticals is http://www.inovio.com. How can I contact Inovio Pharmaceuticals? Inovio Pharmaceuticals' mailing address is 660 WEST GERMANTOWN PIKE SUITE 110, PLYMOUTH MEETING PA, 19462. The biopharmaceutical company can be reached via phone at 267-440-4200 or via email at [email protected] MarketBeat Community Rating for Inovio Pharmaceuticals (NASDAQ INO)Community Ranking: 3.1 out of 5 ( )Outperform Votes: 514 (Vote Outperform)Underperform Votes: 310 (Vote Underperform)Total Votes: 824MarketBeat's community ratings are surveys of what our community members think about Inovio Pharmaceuticals and other stocks. Vote "Outperform" if you believe INO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/19/2019 by MarketBeat.com StaffFeatured Article: What is a capital gain?